Skip to main content

Home

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »

Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video

IN FOCUS | Obesity & lifestyle interventions

Doctor measures a man's waist

07-03-2023 | Type 2 diabetes | News

‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

IN FOCUS | Hypoglycemia

Data for health analytics concept

03-03-2023 | Healthcare systems | News

Health informatics system aids timely, equitable diabetes care

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

IN FOCUS | Cardiovascular disorders

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

IN FOCUS | Tirzepatide

Doctor measures a man's waist

07-03-2023 | Type 2 diabetes | News

‘Substantial’ bodyweight reductions with tirzepatide in people with type 2 diabetes and obesity

SURMOUNT-2 trial results show bodyweight reductions with tirzepatide that rival those seen with other approved anti-obesity medications in people with type 2 diabetes.

IN FOCUS | Mental health & psychosocial care

Lori Berard

04-14-2022 | Hyperglycemia | View from the clinic | Article

Managing hyperglycemia related to stress

Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.

IN FOCUS | GLP-1 receptor agonists

Syringe and pills

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

IN FOCUS | Pediatric type 2 diabetes

Weekly pill container

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.